| First Author | Patel R | Year | 2017 |
| Journal | Endocrinology | Volume | 158 |
| Issue | 4 | Pages | 1034-1047 |
| PubMed ID | 28324010 | Mgi Jnum | J:247311 |
| Mgi Id | MGI:5915064 | Doi | 10.1210/en.2017-00094 |
| Citation | Patel R, et al. (2017) Separating the Anti-Inflammatory and Diabetogenic Effects of Glucocorticoids Through LXRbeta Antagonism. Endocrinology 158(4):1034-1047 |
| abstractText | Synthetic glucocorticoids (GCs), including dexamethasone (DEX), are powerful anti-inflammatory drugs. Long-term use of GCs, however, can result in metabolic side effects such as hyperglycemia, hepatosteatosis, and insulin resistance. The GC receptor (GR) and liver X receptors (LXRalpha and LXRbeta) regulate overlapping genes involved in gluconeogenesis and inflammation. We have previously shown that Lxrbeta-/- mice are resistant to the diabetogenic effects of DEX but still sensitive to its immunosuppressive actions. To determine whether this finding could be exploited for therapeutic intervention, we treated mice with GSK2033, a pan-LXR antagonist, alone or combined with DEX. GSK2033 suppressed GC-induced gluconeogenic gene expression without affecting immune-responsive GR target genes. The suppressive effect of GSK2033 on DEX-induced gluconeogenic genes was specific to LXRbeta, was liver cell autonomous, and occurred in a target gene-specific manner. Compared with DEX treatment alone, the coadministration of GSK2033 with DEX decreased the recruitment of GR and its accessory factors MED1 and C/EBPbeta to the phosphoenolpyruvate carboxykinase promoter. However, GSK2033 had no effect on DEX-mediated suppression of inflammatory genes expressed in the liver or in mouse primary macrophages stimulated with lipopolysaccharides. In conclusion, our study provides evidence that the gluconeogenic and immunosuppressive actions of GR activation can be mechanistically dissociated by pharmacological antagonism of LXRbeta. Treatment with an LXRbeta antagonist could allow the safer use of existing GC drugs in patients requiring chronic dosing of anti-inflammatory agents for the treatment of diseases such as rheumatoid arthritis and inflammatory bowel disease. |
